Back to results
US 2022/0064329 A1Published application
Bispecific antibodies
AssigneeNovo Nordisk A/S
InventorsPrafull S. Gandhi, Jens Breinholt, Henrik Oestergaard
Life of this patent
Estimating the term…
Abstract
The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.
Claims11
A bispecific antibody comprising
- (i) a first antigen binding site capable of binding Factor VII(a), and
- (ii) a second antigen binding site capable of binding TREM-like Transcript 1 (TLT-1);
- wherein the first antigen-binding site comprises:
- a CDRL1 represented by SEQ ID NO:
- 847,
- a CDRL2 represented by SEQ ID NO:
- 848,
- a CDRL3 represented by SEQ ID NO:
- 849,
- a CDRH1 represented by SEQ ID NO:
- 851,
- a CDRH2 represented by SEQ ID NO:
- 852, and
- a CDRH3 represented by SEQ ID NO:
- 853;
- wherein the second antigen-binding site comprises:
- a CDRL1 represented by SEQ ID NO:
- 855,
- a CDRL2 represented by SEQ ID NO:
- 856,
- a CDRL3 represented by SEQ ID NO:
- 857,
- a CDRH1 represented by SEQ ID NO:
- 859,
- a CDRH2 represented by SEQ ID NO:
- 860, and
- a CDRH3 represented by SEQ ID NO:
- 861;
- and
- wherein the antibody comprises an Fc region.
27 more elements
-11. (canceled)
(canceled)
A method for treating a coagulopathy in an individual, comprising administering an effective amount of a bispecific antibody to the individual;
- wherein the bispecific antibody comprises:
- (i) a first antigen binding site capable of binding Factor VII(a);
- and
- (ii) a second antigen binding site capable of binding TREM-like Transcript 1 (TLT-1);
- wherein the first antigen-binding site comprises:
- a CDRL1 represented by SEQ ID NO:
- 847,
- a CDRL2 represented by SEQ ID NO:
- 848,
- a CDRL3 represented by SEQ ID NO:
- 849,
- a CDRH1 represented by SEQ ID NO:
- 851,
- a CDRH2 represented by SEQ ID NO:
- 852, and
- a CDRH3 represented by SEQ ID NO:
- 853;
- wherein the second antigen-binding site comprises:
- a CDRL1 represented by SEQ ID NO:
- 855,
- a CDRL2 represented by SEQ ID NO:
- 856,
- a CDRL3 represented by SEQ ID NO:
- 857,
- a CDRH1 represented by SEQ ID NO:
- 859,
- a CDRH2 represented by SEQ ID NO:
- 860, and
- a CDRH3 represented by SEQ ID NO:
- 861;
- wherein the coagulopathy is selected from the group consisting of hemophilia A, with or without inhibitors;
- hemophilia B, with or without inhibitors;
- FVII(a) deficiency;
- and Glanzmann's thrombasthenia.
31 more elements
Dependencies are inferred from the claim text.